Heterologous expression, biochemical characterisation and computational analysis of Bacteroides fragilis enolase

Ugurel E., Kocer S., Sariyer E., MUTLU Ö., Inci T. G., Ugurel O. M., ...Daha Fazla

Computational Biology and Chemistry, cilt.98, 2022 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 98
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1016/j.compbiolchem.2022.107658
  • Dergi Adı: Computational Biology and Chemistry
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Applied Science & Technology Source, BIOSIS, Biotechnology Research Abstracts, Chemical Abstracts Core, Chimica, Compendex, Computer & Applied Sciences, EMBASE, INSPEC, MEDLINE, zbMATH
  • Anahtar Kelimeler: Antibiotic resistance, Bacteriodes fragilis, Enolase, Enzyme kinetic, In silico studies, Structure-based drug design
  • Yıldız Teknik Üniversitesi Adresli: Evet

Özet

© 2022Bacteriodes fragilis is an anaerobic bacterium found in the human intestinal flora. In this study, BfEno was targeted with a structure-based drug design approach because inhibition of this enzyme may prevent both the aerobic and anaerobic pathways due to its role in the glycolytic pathway. First, the gene encoding BfEno was cloned, expressed and the protein produced over 95% purity. The Km and Vmax values of BfEno were determined as 314.9 µM and 256.2 µmol/min.mg, respectively. Drug-like chemicals were retrieved from the ZINC database for high-throughput virtual screening analyses. As a result of screening study, the ZINC91441604 has been proposed to bind to the active site of the enzyme and remain stable. The same compound exhibited weak binding to the human enolases than the bacterial enolase. Hence, ZINC91441604 may be proposed as a novel candidate for further in vitro and in vivo drug analysis towards the treatment of B. fragilis infections.